All lobbying filings

FORBES-TATE

Lobbying for AMGEN USA, INC. · Biotech company that discovers, develops, manufactures and delivers human theraputics

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 19, 2025

Income

$80,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 4

Taxation/Internal Revenue Code

Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Medicare/Medicaid

Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Medical/Disease Research/Clinical Labs

Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Budget/Appropriations

Issues regarding implementation of the Consolidated Appropriations Act, 2021 (PL 116-260); Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.